Earlier this month, a series of announcements by Hong Kong-listed CSPC PHARMA (01093.HK) brought renewed attention to the asset restructuring incident involving its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ) from a year ago. With China's securities regulator imposing penalties on four individuals—Pan Weidong, Zhang Heming, Du Ying, and Zhen Hong—details of the insider trading case have become clearer.
On November 3, CSPC PHARMA disclosed that executive director Pan Weidong received a penalty notice from the China Securities Regulatory Commission (CSRC) related to transactions involving subsidiary CSPC Innovation. Pan subsequently resigned as executive director and authorized representative, citing personal reasons. While the CSRC's October 16 penalty notices didn't specify the companies involved, CSPC's November 3 filing revealed the case stemmed from CSPC Innovation's January 2024 announcement of plans to acquire another CSPC subsidiary, Shijiazhuang Pharmaceutical Group Baik Bio-Pharmaceutical Co., Ltd. (Shijiazhuang Baik), for 100% ownership—a deal ultimately terminated in April 2025.
The CSRC found that Pan used the securities account of CSPC Innovation's controlling shareholder, NBP Pharmaceutical, to purchase 2.74 million shares of CSPC Innovation between December 8-20, 2023, totaling nearly 100 million yuan. Despite resulting in losses, Pan was fined 5 million yuan for clear insider trading characteristics, including attempts to evade regulatory inquiries. Three other individuals were also penalized: Zhang Heming (confiscation of 152,240 yuan profits plus 1.5 million yuan fine), Du Ying (370,410 yuan profits plus 1.5 million yuan fine), and Zhen Hong (794,690 yuan profits plus 2.38 million yuan fine). All four had close ties to CSPC Group or its subsidiaries.
The case has raised corporate governance concerns, particularly regarding Pan's use of a major shareholder's account for transactions—a practice that blurs boundaries between corporate and shareholder activities. CSPC stated the penalties won't significantly impact operations, but market observers question internal oversight mechanisms.
Meanwhile, Hebei billionaire Cai Dongchen's CSPC PHARMA continues restructuring its innovative drug assets through CSPC Innovation. Since 2023, the subsidiary has undergone strategic repositioning, including an 18.71 billion yuan investment to acquire 51% of mRNA specialist CSPC JUSHI in August 2023, a corporate rebranding in November 2023, and an additional 1.1 billion yuan purchase in October 2025 to raise its JUSHI stake to 80%. The terminated Shijiazhuang Baik acquisition would have further consolidated CSPC's innovative drug platform.
Financially, CSPC Innovation has faced pressure since taking on innovative drug assets. While 2023 pre-adjustment net profits rose 4.03% to 756 million yuan, adjusted figures showed a 13.63% decline to 434 million yuan. The downturn accelerated in 2024 with an 87.63% profit plunge to 53.73 million yuan, followed by a 117.26% year-on-year decrease to -24.05 million yuan in the first nine months of 2025, including a tenfold Q3 profit decline.
CSPC PHARMA, listed since 1994 and led by 72-year-old chairman Cai Dongchen (ranked 1,796th on Hurun's 2025 Global Rich List with 15.5 billion yuan wealth), maintains two core businesses: finished drugs (spanning neurology, oncology, anti-infectives, and cardiovascular) and APIs (including vitamin C, antibiotics, and caffeine products). The group's innovative drug strategy now centers on CSPC Innovation as the primary platform.